Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial

Knapen MH, Braam LA, Drummen NE, et al. · Thrombosis and Haemostasis

The three-year trial closest to a consumer dose: MK-7 cut circulating inactive matrix Gla protein by 50% versus placebo and significantly reduced carotid-femoral pulse wave velocity and the stiffness index beta across the whole group, with local carotid measures improving in the women whose baseline stiffness was above the median. Inflammatory and endothelial markers did not change.

Population

Healthy postmenopausal women (120 MK-7, 124 placebo), 3 years

Intervention

MK-7 180 ug/day

Comparator

Placebo

Limitations

Healthy postmenopausal women only; arterial stiffness is a surrogate for cardiovascular events; the most striking effects are in a pre-specified high-stiffness subgroup; the supplement was supplied by its manufacturer.